• #1064517
  • 555
  • Glaxo Smith Kline #58160095509

Menveo® Meningitis Vaccine Indicated for People 2 Months Through 55 Years of Age Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL

MENVEO VACCINE, SDV 10-5MG/0.5ML (5/CT)

Glaxo Smith Kline 58160095509
Glaxo Smith Kline 58160095509
Glaxo Smith Kline 58160095509
Menveo® Meningitis Vaccine Indicated for People 2 Months Through 55 Years of Age Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL
Menveo® Meningitis Vaccine Indicated for People 2 Months Through 55 Years of Age Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL
Menveo® Meningitis Vaccine Indicated for People 2 Months Through 55 Years of Age Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL
Compare
Features
  • MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
  • MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
  • More …
  Log In to Order
or
 View Alternatives

Product Specifications

Features
  • MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
  • MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
More Information

Professionals Also Viewed

  • #1047522
  • 562
  • Glaxo Smith Kline #58160097620
Bexsero® Meningitis Vaccine Indicated for People 10 Through 25 Years of Age Meningococcal Group B Vaccine 50 mcg - 50 mcg / 0.5 mL Injection Prefilled Syringe 0.5 mL
  • BEXSERO is a vaccine indicated for active immunization to prevent inva …
  • BEXSERO is approved for use in individuals 10 through 25 years of age
  • BEXSERO is supplied as a 0.5 mL suspension in a glass pre-filled syrin …
  • #944569
  • 198
  • Pfizer #00005010005
Trumenba® Meningitis Vaccine Indicated for People 10 Through 25 Years of Age Meningococcal Group B Vaccine 120 mcg / 0.5 mL Injection Prefilled Syringe 0.5 mL
  • Trumenba is indicated for active immunization to prevent invasive dise …
  • Trumenba is a suspension for intramuscular injection in 0.5 mL single- …
  • 5 Syringes
  • #944570
  • 101
  • Pfizer #00005010010
Trumenba® Meningitis Vaccine Indicated for People 10 Through 25 Years of Age Meningococcal Group B Vaccine 120 mcg / 0.5 mL Injection Prefilled Syringe 0.5 mL
  • Trumenba is indicated for active immunization to prevent invasive dise …
  • Trumenba is a suspension for intramuscular injection in 0.5 mL single- …
  • 10 Syringes
  • #1191780
  • 967
  • Sanofi Pasteur #49281059005
MenQuadfi™ Meningitis Vaccine Indicated for People 2 Years of Age and Older Meningococcal (Groups A, C, Y, and W-135) Conjugate Vaccine, Preservative Free 10 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL
  • MenQuadfi is a vaccine indicated for active immunization for the preve …
Compare Products (0) Clear Compare